Drugs / XJ101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06014736 | Aug 2023 → Mar 2024 | staphylococcus aureus infection | Starmab biologics（Shanghai）Co,.ltd | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XJ101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06014736 ↗ |
| Modality | Protein / enzyme biologic | “XJ101 is a recombinant humanized single domain antibody-Fc (human immunoglobulin G1 type) fusion protein.” NCT06014736 ↗ |
| Route | Intravenous | “XJ101 via intravenous(IV).” NCT06014736 ↗ |